Skip to content
DTIL·Nasdaq·US

Precision BioSciences

Precision BioSciences is a clinical stage gene editing company that uses its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies for genetic and infectious diseases, competing with other genome and epigenomic editing companies in the biotechnology and pharmaceutical industries.

Source: SEC 10-K Mar 12, 2026

Thematic Position

DTIL

Relationship Groups

Partners3
Licensing5
Competitors8

Relationship details are part of the Pro plan.

Recent Discoveries

Recent discoveries are part of the Pro plan.

Ended Relationships

17 ended relationships · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

government funding conditionmanufacturing requirement
Bayh-Dole Act requires U.S. manufacturing for Duke-licensed government-funded inventions
SEC 10-QMay 5, 2026

The full regulatory passage is part of the Pro plan.

11 more · Regulatory and geopolitical insights are part of the Pro plan.

Disclosed customers above 10% of revenue

2 customers · Named major customers are part of the Pro plan.